Neisseria meningitidis Infections - Pipeline Review, H1 2018

  • ID: 4518514
  • Report
  • 74 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • GlaxoSmithKline Plc
  • ImmunoBiology Ltd
  • Johnson & Johnson
  • MGB Biopharma Ltd
  • Pfizer Inc
  • MORE
Neisseria meningitidis Infections - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H1 2018, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

Report Highlights:

This latest pipeline guide Neisseria meningitidis Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 2, 2, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • GlaxoSmithKline Plc
  • ImmunoBiology Ltd
  • Johnson & Johnson
  • MGB Biopharma Ltd
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Neisseria meningitidis Infections - Overview

Neisseria meningitidis Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neisseria meningitidis Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neisseria meningitidis Infections - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

China National Pharmaceutical Group Corp

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

ImmunoBiology Ltd

Johnson & Johnson

MGB Biopharma Ltd

Pfizer Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Wellstat Vaccines LLC

Neisseria meningitidis Infections - Drug Profiles

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae [serotype B] + meningococcal) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MenBioVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, B, C] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W135] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes C, Y] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGBBP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCL-195 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06886992 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis Infections - Dormant Projects

Neisseria meningitidis Infections - Discontinued Products

Neisseria meningitidis Infections - Product Development Milestones

Featured News & Press Releases

Sep 12, 2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease

Jul 11, 2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection

Mar 24, 2017: GSK Announces Availability of Menveo (meningococcal ACWY vaccine)

Dec 24, 2014: Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial

Aug 01, 2013: US FDA expands Novartis' Menveo indication for infants aged two months

Feb 25, 2013: CanSinotech submitted CTA of “ACW135Y Meningococcal Conjugate Vaccine” to CFDA

Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Menveo

Feb 13, 2012: FDA Requests Additional Data On Novartis's Quadrivalent Meningococcal Conjugate Vaccine, Menveo For Expanded Use In Infants And Toddlers

Jun 16, 2011: FDA Accepts Novartis's Menveo sBLA For Review

May 12, 2011: Novartis Provides Update On Phase III Study Of Menveo Vaccine To Treat Meningococcal Disease

Jan 31, 2011: FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo, for use in children from 2 years of age

Oct 25, 2010: Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants

Jun 08, 2010: Novartis receives Health Canada approval of Menveo to prevent meningococcal disease

Mar 31, 2010: New vaccine can protect travelers against four types of meningitis

Mar 18, 2010: Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Neisseria meningitidis Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018

Neisseria meningitidis Infections - Pipeline by Biological E Ltd, H1 2018

Neisseria meningitidis Infections - Pipeline by China National Pharmaceutical Group Corp, H1 2018

Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2018

Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H1 2018

Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, H1 2018

Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, H1 2018

Neisseria meningitidis Infections - Pipeline by MGB Biopharma Ltd, H1 2018

Neisseria meningitidis Infections - Pipeline by Pfizer Inc, H1 2018

Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H1 2018

Neisseria meningitidis Infections - Pipeline by Serum Institute of India Ltd, H1 2018

Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, H1 2018

Neisseria meningitidis Infections - Dormant Projects, H1 2018

Neisseria meningitidis Infections - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Neisseria meningitidis Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • China National Pharmaceutical Group Corp
  • Chongqing Zhifei Biological Products Co Ltd
  • GlaxoSmithKline Plc
  • ImmunoBiology Ltd
  • Johnson & Johnson
  • MGB Biopharma Ltd
  • Pfizer Inc
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Wellstat Vaccines LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll